Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Status:
Terminated
Trial end date:
2016-12-08
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of romidepsin when given
together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well they
work in treating patients with metastatic inflammatory breast cancer. Romidepsin may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving romidepsin and paclitaxel albumin-stabilized nanoparticle
formulation may be an effective treatment for inflammatory breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University